LabGenomics Successfully Concludes MedLab 2024... Establishes Foundation for Entry into Middle East Diagnostic Market

LabGenomics announced on the 14th that it successfully concluded the Middle East's largest diagnostic and medical device exhibition, 'Medlab Middle East 2024,' held at the Dubai World Trade Center from the 5th to the 8th (local time).

The company stated, "We received positive feedback during networking and product promotion at Medlab," adding, "We have laid the foundation for entering the Middle Eastern diagnostic market, and discussions are underway as the supply of our diagnostic products to three Middle Eastern countries?United Arab Emirates (UAE), Oman, and Jordan?is expected."

At Medlab, LabGenomics showcased ▲ non-invasive prenatal testing (NIPT) such as Mamguard ▲ oral microbiome test Bioralcare ▲ vaginal microbiome test PinkBiomecare ▲ FRAXA diagnostic kit (LabGscan FRAXA™ Diagnostic Kit) ▲ and Exome Kit.

In particular, this year, there was strong buyer interest in the whole exome sequencing (WES)-based diagnostic service and Bioralcare diagnostic products. The company expects additional contracts beyond the supply agreements currently under discussion with the three countries.

A LabGenomics representative emphasized, "The Middle East region is expected to see growth in the diagnostic market due to population increase and rising disease incidence," adding, "Starting with this Middle East entry, we will promote LabGenomics' NGS (next-generation sequencing) technology and strengthen our position and influence in the global market."

This content was produced with the assistance of AI translation services.